Oryza Sativa Recombinant HSA Liquid For Embryo Cryopreservation

Recombinant human serum albumin liquid for Embryo Cryopreservation

Description

Embryo cryopreservation, a process of freezing and storing embryos, is a vital part of most in vitro fertilization(IVF) programs. When the first IVF trail failed, the embryos are then thawed and used for second trail or more times. The process is chosen for reasons as varied as providing an additional chance for pregnancy or saving embryos in the face of certain medical treatments. During the freezing, the application of cryopreservation fluid can play a role in protecting embryonic cells, and one of the most important components is human serum albumin (HSA).

At present, the HSA is mainly from human blood donations, which may bring risks of infection with viruses such as AIDS, hepatitis B, and C viruses, as well as unknown pathogens. In addition, cryopreservation agent manufactures may suffer the risk of shortage of HSA supply due to blood source restrictions.

Wuhan Healthgen Biotechnology Corp.(Healthgen Biotech), a high-tech enterprise specializing in plant-derived pharmaceutical research and development, has successfully developed a series of pharmaceutical products, plant-derived Recombinant Human Serum Albumin(OsrHSA) as the representative, by its two-core patented technology platform: rice endosperm specific expression platform(Oryz^HiExp) and proteins purification platform(Oryz^Pur).

Using the animal component free OsrHSA in cell cryopreservation agent to protect embryo cells, there are such advantages:

1) Chemical defined, no unknown ingredients and will not induce undirected differentiation .

2) Safe and non-toxic, safer than DMSO while protecting embryo cells.

3) High batch consistency, avoid interference of different batches of serum on gametes and embryonic cells.

4) Animal or human component free, ethically safe, and eliminate or reduce of the potential risks of infection with viruses such as AIDS, hepatitis B, and C viruses, as well as unknown pathogens.

5) One-metric ton capacity and stable supply, cryopreservation agent manufacturers will not worry about the shortage of HSA due to insufficient plasma sources.